The DOI matches its Crossref record; 329 of the 329 references it cites were found in a registry or an index.
Neurotoxin-based models of Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
The Principles of Humane Experimental Technique
(1960) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1960.tb73127.x · Cited by 4,912
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“These non-motor symptoms include neuropsychiatric and sleep disorders, olfactory deficits, constipation, and male erectile dysfunction among others (Chaudhuri et al., 2006).”
BackgroundMitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Ungerstedt, U., & Arbuthnott, G. W. (1970) · Brain Research · doi:10.1016/0006-8993(70)90187-3 · Cited by 1,978
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11000.x · Cited by 1,922
Reversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus
Bergman, H., Wichmann, T., & DeLong, M. R. (1990) · Science · doi:10.1126/science.2402638 · Cited by 1,907
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., & Benabid, A.-L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391603 · Cited by 1,853
Rotenone, Paraquat, and Parkinson’s Disease
Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., Marras, C., Bhudhikanok, G. S., Kasten, M., Chade, A. R., et al. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002839 · Cited by 1,475
6-hydroxy-dopamine induced degeneration of central monoamine neurons
Ungerstedt, U. (1968) · European Journal of Pharmacology · doi:10.1016/0014-2999(68)90164-7 · Cited by 1,460
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11001.x · Cited by 1,290
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263
Nicklas, W. J., Vyas, I., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,262
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“All these elements have been identified in PD (Hartmann et al., 2000; Gerhard et al., 2006; Alam et al., 1997a,b; Schapira et al., 1990).”
BackgroundBrochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Björklund, L. M., Sánchez-Pernaute, R., Chung, S., Andersson, T., Chen, I. Y. C., McNaught, K. S. P., Brownell, A.-L., Jenkins, B. G., Wahlestedt, C., Kim, K.-S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022438099 · Cited by 1,170
Protocol for the MPTP mouse model of Parkinson's disease
Jackson-Lewis, V., & Przedborski, S. (2007) · Nature Protocols · doi:10.1038/nprot.2006.342 · Cited by 1,111
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,063
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 2×
“In the acute mouse model, astrocytosis parallels dopaminergic-cell death (Liberatore et al., 1999; Członkowska et al., 1996; Kohutnicka et al., 1998), suggesting that astrocytic reaction is secondary to the neuronal death.”
BackgroundDopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice
Heikkila, R. E., Hess, A., & Duvoisin, R. C. (1984) · Science · doi:10.1126/science.6610213 · Cited by 1,009
Description of Parkinson's Disease as a Clinical Syndrome
FAHN, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 977
Dopamine depletion impairs precursor cell proliferation in Parkinson disease
Höglinger, G. U., Rizk, P., Muriel, M. P., Duyckaerts, C., Oertel, W. H., Caille, I., & Hirsch, E. C. (2004) · Nature Neuroscience · doi:10.1038/nn1265 · Cited by 944
William Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Cohen, G., Heikkila, R. E., & MacNamee, W. T. T. A. O. D. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42751-8 · Cited by 897
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
McCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., & Di Monte, D. A. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0507 · Cited by 838
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.10 · Cited by 833 · cited 1×
“The average age at onset is 60, with age being an irrefutable risk factor for this idiopathic disease (de Rijk et al., 1997).”
BackgroundPathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Self-citationRoy, N. S., Cleren, C., Singh, S. K., Yang, L., Beal, M. F., & Goldman, S. A. (2006) · Nature Medicine · doi:10.1038/nm1495 · Cited by 821
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 803
A highly reproducible rotenone model of Parkinson's disease
Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.016 · Cited by 795
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984) · Nature · doi:10.1038/311464a0 · Cited by 786
Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway
Deumens, R., Blokland, A., & Prickaerts, J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7891 · Cited by 758
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739 · cited 1×
“As discussed by us in a previous review (Bove et al., 2005a), the administration of rotenone by means of an osmotic pump gives rise to a highly variable dopaminergic lesion, ranging from virtually absent to close to complete (Betarbet et al., 2000; Sherer et al., 2003; Hoglinger et al., 2003;…”
BackgroundSelf-citationHartmann, A., Hunot, S., Michel, P. P., Muriel, M.-P., Vyas, S., Faucheux, B. A., Mouatt-Prigent, A., Turmel, H., Srinivasan, A., Ruberg, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556597 · Cited by 715
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., & Rüb, U. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1301-4 · Cited by 708
Sherer, T. B., Kim, J.-H., Betarbet, R., & Greenamyre, J. T. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8072 · Cited by 708
The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice
Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., & Di Monte, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100560200 · Cited by 684
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00285.x · Cited by 641
Origin and functional consequences of the complex I defect in Parkinson's disease
Swerdlow, R. H., Parks, J. K., Miller, S. W., Davis, R. E., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., Bennett, J. P., & Parker, W. D. (1996) · Annals of Neurology · doi:10.1002/ana.410400417 · Cited by 638
Gerfen, C. R., Baimbridge, K. G., & Miller, J. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8780 · Cited by 635
On the Presence of 3-Hydroxytyramine in Brain
CARLSSON, A., LINDQVIST, M., MAGNUSSON, T., & WALDECK, B. (1958) · Science · doi:10.1126/science.127.3296.471 · Cited by 634
Olsson, M., Nikkhah, G., Bentlage, C., & Bjorklund, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03863.1995 · Cited by 625
Environmental risk factors and Parkinson's disease: A case‐control study in Taiwan
Liou, H. H., Tsai, M. C., Chen, C. J., Jeng, J. S., Chang, Y. C., Chen, S. Y., & Chen, R. C. (1997) · Neurology · doi:10.1212/wnl.48.6.1583 · Cited by 616
Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609
The “staircase test”: a measure of independent forelimb reaching and grasping abilities in rats
Montoya, C. P., Campbell-Hope, L. J., Pemberton, K. D., & Dunnett, S. B. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90048-5 · Cited by 609
Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
Sofic, E., Lange, K. W., Jellinger, K., & Riederer, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90355-b · Cited by 590
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W., Kholodilov, N., Vila, M., Trillat, A.-C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 581
Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031326.x · Cited by 547
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409713102 · Cited by 526
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization
Hefti, F., Melamed, E., & Wurtman, R. J. (1980) · Brain Research · doi:10.1016/0006-8993(80)90871-9 · Cited by 501
Different data from different labs: Lessons from studies of gene–environment interaction
Wahlsten, D., Metten, P., Phillips, T. J., Boehm, S. L., Burkhart‐Kasch, S., Dorow, J., Doerksen, S., Downing, C., Fogarty, J., Rodd‐Henricks, K., et al. (2003) · Journal of Neurobiology · doi:10.1002/neu.10173 · Cited by 495
Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats
Alam, M., & Schmidt, W. J. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00180-8 · Cited by 473
Thiruchelvam, M., Richfield, E. K., Baggs, R. B., Tank, A. W., & Cory-Slechta, D. A. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09207.2000 · Cited by 471
Tatton, N. A., & Kish, S. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00545-3 · Cited by 468
Przedbroski, S., Leviver, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., & Togasaki, D. M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00066-r · Cited by 453
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3039 · Cited by 449
Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease
Karachi, C., Grabli, D., Bernard, F. A., Tandé, D., Wattiez, N., Belaid, H., Bardinet, E., Prigent, A., Nothacker, H.-P., Hunot, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42642 · Cited by 434
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease
Sedelis, M., Schwarting, R. K. W., & Huston, J. P. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00309-6 · Cited by 432
Winkler, C., Kirik, D., Björklund, A., & Cenci, M. A. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0499 · Cited by 430
Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 426
Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss
Brooks, A. I., Chadwick, C. A., Gelbard, H. A., Cory-Slechta, D. A., & Federoff, H. J. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01192-5 · Cited by 424
Cicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Van Woert, M. H., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 402
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400 · cited 1×
“…studies in three individuals who survived 3–16 years after exposure to MPTP (Langston et al., 1999) and in six monkeys who survived 5–14 years after exposure to MPTP (McGeer et al., 2003) showed activated microglia, which is indicative of an ongoing degenerative process with neuroinflammation.”
BackgroundVila, M., Vukosavic, S., Jackson‐Lewis, V., Neystat, M., Jakowec, M., & Przedborski, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740721.x · Cited by 388
Kurkowska-Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
Iancu, R., Mohapel, P., Brundin, P., & Paul, G. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.023 · Cited by 376
Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 372
Pooled Analysis of Tobacco Use and Risk of Parkinson Disease
Ritz, B., Ascherio, A., Checkoway, H., Marder, K. S., Nelson, L. M., Rocca, W. A., Ross, G. W., Strickland, D., Van Den Eeden, S. K., & Gorell, J. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.990 · Cited by 370
Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models
Hu, L., Lu, M., Tiong, C. X., Dawe, G. S., Hu, G., & Bian, J. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00543.x · Cited by 365 · cited 1×
“The striatal model is mainly being used to unmask the pathogenesis of PD and to test neuroprotective strategies (Hu et al., 2010, 2011).”
MethodSriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002) · The FASEB Journal · doi:10.1096/fj.02-0216fje · Cited by 362
Parkinson’s disease risk from ambient exposure to pesticides
Wang, A., Costello, S., Cockburn, M., Zhang, X., Bronstein, J., & Ritz, B. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9574-5 · Cited by 349
Hassani, O.-K., Mouroux, M., & Féger, J. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00535-8 · Cited by 345
Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J.-H., Lund, S., Na, H.-M., Taylor, G., Bence, N. F., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.003 · Cited by 342
Gerfen, C., Baimbridge, K., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03935.1987 · Cited by 338
Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo
Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., & Schulz, J. B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742213.x · Cited by 337
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats
Höglinger, G. U., Féger, J., Prigent, A., Michel, P. P., Parain, K., Champy, P., Ruberg, M., Oertel, W. H., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01533.x · Cited by 331
Petroske, E., Meredith, G. E., Callen, S., Totterdell, S., & Lau, Y.-S. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00295-0 · Cited by 331
Thiruchelvam, M., Brockel, B. J., Richfield, E. K., Baggs, R. B., & Cory-Slechta, D. A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02496-3 · Cited by 324
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset
Jenner, P. G., Rupniak, N. M. J., Rose, S., Kelly, E., Kilpatrick, G. J., Lees, A. J., & MARSDEN, C. D. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90467-1 · Cited by 323
Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90498-c · Cited by 319
GERMAN, D. C., MANAYE, K. F., SONSALLA, P. K., & BROOKS, B. A. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb24523.x · Cited by 318
Soto‐Otero, R., Méndez‐Álvarez, E., Hermida‐Ameijeiras, Á., Muñoz‐Patiño, A. M., & Labandeira‐Garcia, J. L. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741605.x · Cited by 314
The 6-hydroxydopamine model: News from the past
Blandini, F., Armentero, M.-T., & Martignoni, E. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.015 · Cited by 311
Paraquat and Parkinson's disease
Berry, C., La Vecchia, C., & Nicotera, P. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.217 · Cited by 309
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
Perier, C., Tieu, K., Guégan, C., Caspersen, C., Jackson-Lewis, V., Carelli, V., Martinuzzi, A., Hirano, M., Przedborski, S., & Vila, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508215102 · Cited by 308
Self-citationThe Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation
Lotharius, J., & O'Malley, K. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005385200 · Cited by 306
Zaidel, A., Spivak, A., Grieb, B., Bergman, H., & Israel, Z. (2010) · Brain · doi:10.1093/brain/awq144 · Cited by 305
Heikkila, R. E., Nicklas, W. J., Vyas, I., & Duvoisin, R. C. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90580-4 · Cited by 300
Ben‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299
Glutathione peroxidase activity in Parkinson's disease brain
Kish, S. J., Morito, C., & Hornykiewicz, O. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90078-3 · Cited by 299
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death
Jeon, B. S., Jackson-Lewis, V., & Burke, R. E. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0016 · Cited by 289
Przedborski, S., & Vila, M. (2003) · PubMed · Cited by 286
Kohutnicka, M., Lewandowska, E., Kurkowska-Jastrzębska, I., Członkowski, A., & Członkowska, A. (1998) · Immunopharmacology · doi:10.1016/s0162-3109(98)00022-8 · Cited by 283
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
Członkowska, A., Kohutnicka, M., Kurkowska-Jastrzębska, I., & Członkowski, A. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0020 · Cited by 279
Role of oxidative stress in paraquat‐induced dopaminergic cell degeneration
McCormack, A. L., Atienza, J. G., Johnston, L. C., Andersen, J. K., Vu, S., & Di Monte, D. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03088.x · Cited by 278
Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat
Shimizu, K., Ohtaki, K., Matsubara, K., Aoyama, K., Uezono, T., Saito, O., Suno, M., Ogawa, K., Hayase, N., Kimura, K., et al. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02577-x · Cited by 263
Inden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04440.x · Cited by 260
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology
Drolet, R. E., Cannon, J. R., Montero, L., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.017 · Cited by 257
Diagnosis and the premotor phase of Parkinson disease
Tolosa, E., Gaig, C., Santamaría, J., & Compta, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e318198db11 · Cited by 255
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration
Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z., & Di Monte, D. A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.008 · Cited by 254
Lee, C. S., Sauer, H., & Björklund, A. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00571-4 · Cited by 248
Chang, J.-W., Wachtel, S. R., Young, D., & Kang, U.-J. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00217-6 · Cited by 248
Costa, J., Lunet, N., Santos, C., Santos, J., & Vaz-Carneiro, A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091525 · Cited by 247
CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease
Pabon, M. M., Bachstetter, A. D., Hudson, C. E., Gemma, C., & Bickford, P. C. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-9 · Cited by 241
Rapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain
Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W., & Di Monte, D. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02134.x · Cited by 241
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Bjorklund, A., Bezard, E., et al. (2008) · Brain · doi:10.1093/brain/awn235 · Cited by 241
α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration
Manning-Boğ, A. B., McCormack, A. L., Purisai, M. G., Bolin, L. M., & Di Monte, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03095.2003 · Cited by 240
Pesticide/Environmental Exposures and Parkinson's Disease in East Texas
Dhillon, A. S., Tarbutton, G. L., Levin, J. L., Plotkin, G. M., Lowry, L. K., Nalbone, J. T., & Shepherd, S. (2008) · Journal of Agromedicine · doi:10.1080/10599240801986215 · Cited by 238
Depino, A. M., Earl, C., Kaczmarczyk, E., Ferrari, C., Besedovsky, H., Del Rey, A., Pitossi, F. J., & Oertel, W. H. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03014.x · Cited by 236
Papa, S. M., Engber, T. M., Kask, A. M., & Chase, T. N. (1994) · Brain Research · doi:10.1016/0006-8993(94)90796-x · Cited by 235
MPTP: current concepts and controversies.
Langston, J. W., & Irwin, I. (1986) · PubMed · Cited by 234
Peng, J., Mao, X. O., Stevenson, F. F., Hsu, M., & Andersen, J. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404596200 · Cited by 233
Porter, C. C., Totaro, J. A., & Stone, C. A. (1963) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26555-7 · Cited by 233
Ros-Bernal, F., Hunot, S., Herrero, M. T., Parnadeau, S., Corvol, J.-C., Lu, L., Alvarez-Fischer, D., Carrillo-de Sauvage, M. A., Saurini, F., Coussieu, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017820108 · Cited by 231
Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter
Bezard, E., Gross, C. E., Fournier, M.-C., Dovero, S., Bloch, B., & Jaber, M. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6995 · Cited by 230
FLEMING, S. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.023 · Cited by 230
Perier, C., Bové, J., Wu, D.-C., Dehay, B., Choi, D.-K., Jackson-Lewis, V., Rathke-Hartlieb, S., Bouillet, P., Strasser, A., Schulz, J. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609874104 · Cited by 229
Self-citationThe overall rod performance test in the MPTP-treated-mouse model of Parkinsonism
Rozas, G., López-Martı́n, E., Guerra, M. J., & Labandeira-Garcı́a, J. L. (1998) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(98)00078-8 · Cited by 225
Andrew, R., Watson, D. G., Best, S. A., Midgley, J. M., Wenlong, H., & Petty, R. K. H. (1993) · Neurochemical Research · doi:10.1007/bf00978370 · Cited by 225
Chiueh, C. C., Markey, S. P., Burns, R. S., Johannessen, J. N., Pert, A., & Kopin, I. J. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90221-8 · Cited by 224
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
Ikeda, K., Kurokawa, M., Aoyama, S., & Kuwana, Y. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00694.x · Cited by 224
Smoking duration, intensity, and risk of Parkinson disease
Chen, H., Huang, X., Guo, X., Mailman, R. B., Park, Y., Kamel, F., Umbach, D. M., Xu, Q., Hollenbeck, A., Schatzkin, A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d55f38 · Cited by 223
Oxy-radical toxicity in catecholamine neurons.
Cohen, G. (1984) · PubMed · Cited by 222
Maggio, R., Riva, M., Vaglini, F., Fornai, F., Molteni, R., Armogida, M., Racagni, G., & Corsini, G. U. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062439.x · Cited by 218
Marinova‐Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06189.x · Cited by 217 · cited 1×
“…has been demonstrated that microglial activation in the SNpc precedes the actual cell loss both in the striatal (Cicchetti et al., 2002; Depino et al., 2003) and the MFB models (Marinova-Mutafchieva et al., 2009) and may also account for the delayed phase of neurodegeneration (Harms et al., 2011).”
BackgroundAspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice
Aubin, N., Curet, O., Deffois, A., & Carter, C. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041635.x · Cited by 214
Forno, L. S., DeLanney, L. E., Irwin, I., & Langston, J. W. (1993) · PubMed · Cited by 207
A mechanism of paraquat toxicity involving nitric oxide synthase
Day, B. J., Patel, M., Calavetta, L., Chang, L.-Y., & Stamler, J. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12760 · Cited by 206
Ferrante, R. J., Schulz, J. B., Kowall, N. W., & Beal, M. F. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00008-5 · Cited by 203
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy
Höglinger, G. U., Lannuzel, A., Khondiker, M. E., Michel, P. P., Duyckaerts, C., Féger, J., Champy, P., Prigent, A., Medja, F., Lombes, A., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03493.x · Cited by 203
Przedborski, S., & Ischiropoulos, H. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.685 · Cited by 202
MPTP: Current Concepts and Controversies
Langston, J. W., & Irwin, I. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198612000-00001 · Cited by 199
Fernagut, P. O., Hutson, C. B., Fleming, S. M., Tetreaut, N. A., Salcedo, J., Masliah, E., & Chesselet, M. F. (2007) · Synapse · doi:10.1002/syn.20456 · Cited by 196
Chapter 51 Effects of nigral and striatal grafts on skilled forelimb use in the rat
Montoya, C. P., Astell, S., & Dunnett, S. B. (1990) · Progress in Brain Research · doi:10.1016/s0079-6123(08)62634-5 · Cited by 195
Temporal relationship between cigarette smoking and risk of Parkinson disease
Thacker, E. L., O’Reilly, E. J., Weisskopf, M. G., Chen, H., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2007) · Neurology · doi:10.1212/01.wnl.0000256374.50227.4b · Cited by 194
The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future
Fox, S. H., & Brotchie, J. M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84007-5 · Cited by 191
Tillerson, J. L., Caudle, W. M., Reverón, M. E., & Miller, G. W. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8021 · Cited by 191
MPTP: a review of its mechanisms of neurotoxicity
Przedborski, S., & Vila, M. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00019-6 · Cited by 191
Ryan, R. E., Ross, S. A., Drago, J., & Loiacono, R. E. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703989 · Cited by 188
Rotenone induces non‐specific central nervous system and systemic toxicity
Lapointe, N., St‐Hilaire, M., Martinoli, M., Blanchet, J., Gould, P., Rouillard, C., & Cicchetti, F. (2004) · The FASEB Journal · doi:10.1096/fj.03-0677fje · Cited by 187
Choi, W.-S., Palmiter, R. D., & Xia, Z. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009132 · Cited by 183
Model Experiments on the Molecular Mechanism of Action of 6-Hydroxydopamine
SANER, A., & THOENEN, H. (1971) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12658-8 · Cited by 182
Gründemann, J., Schlaudraff, F., Haeckel, O., & Liss, B. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn084 · Cited by 174
Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys
Villalba, R. M., Lee, H., & Smith, Y. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2008.09.025 · Cited by 171
Luthman, J., Fredriksson, A., Sundström, E., JONSSON, G., & Archer, T. (1989) · Behavioural Brain Research · doi:10.1016/s0166-4328(89)80121-4 · Cited by 169
Inden, M., Kitamura, Y., Abe, M., Tamaki, A., Takata, K., & Taniguchi, T. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.92 · Cited by 168
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease
Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M. J., Kholodilov, N., & Burke, R. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606401103 · Cited by 168
Ottosson, D. R., Iderberg, H., Li, Q., Dekundy, A., Zhang, J., Li, H., Baishen, R., Danysz, W., Bézard, E., & Cenci, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.001 · Cited by 167
A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery
Mounayar, S., Boulet, S., Tandé, D., Jan, C., Pessiglione, M., Hirsch, É. C., Féger, J., Savasta, M., François, C., & Tremblay, L. (2007) · Brain · doi:10.1093/brain/awm208 · Cited by 166
Automated quantitative gait analysis in animal models of movement disorders
Vandeputte, C., Taymans, J.-M., Casteels, C., Coun, F., Ni, Y., Van Laere, K., & Baekelandt, V. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-92 · Cited by 166
Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra
Faull, R. L. M., & Laverty, R. (1969) · Experimental Neurology · doi:10.1016/0014-4886(69)90081-8 · Cited by 165
Bezard, E., Imbert, C., Deloire, X., Bioulac, B., & Gross, C. E. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00531-3 · Cited by 165
Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model
Barraud, Q., Lambrecq, V., Forni, C., McGuire, S., Hill, M. P., Bioulac, B. H., Balzamo, E., Bézard, E., Tison, F., & Ghorayeb, I. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.019 · Cited by 164
Cadet, J. L., Katz, M., Jackson-Lewis, V., & Fahn, S. (1989) · Brain Research · doi:10.1016/0006-8993(89)91530-8 · Cited by 163
Imbert, C., Bézard, E., Guitraud, S., Boraud, T., & Gross, C. E. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(99)00184-3 · Cited by 163
Collier, T. J., Lipton, J., Daley, B. F., Palfi, S., Chu, Y., Sortwell, C., Bakay, R. A. E., Sladek, J. R., & Kordower, J. H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.013 · Cited by 162
Peng, J., Stevenson, F. F., Doctrow, S. R., & Andersen, J. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500984200 · Cited by 160
Alvarez-Fischer, D., Henze, C., Strenzke, C., Westrich, J., Ferger, B., Höglinger, G. U., Oertel, W. H., & Hartmann, A. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.10.012 · Cited by 159
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Hadaczek, P., Eberling, J. L., Pivirotto, P., Bringas, J., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.106 · Cited by 158
Moratalla, R., Quinn, B., DeLanney, L. E., Irwin, I., Langston, J. W., & Graybiel, A. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3859 · Cited by 158
Peng, J., Peng, L., Stevenson, F. F., Doctrow, S. R., & Andersen, J. K. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1569-07.2007 · Cited by 158
The Role of Microglia in Paraquat-Induced Dopaminergic Neurotoxicity
Wu, X.-F., Block, M. L., Zhang, W., Qin, L., Wilson, B., Zhang, W.-Q., Veronesi, B., & Hong, J.-S. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.654 · Cited by 158
Mitchell, I., Cross, A. J., Sambrook, M. A., & Crossman, A. R. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90424-0 · Cited by 157
Consistent behavioral phenotype differences between inbred mouse strains in the IntelliCage
Krackow, S., Vannoni, E., Codita, A., Mohammed, A. H., Cirulli, F., Branchi, I., Alleva, E., Reichelt, A., Willuweit, A., Võikar, V., et al. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00606.x · Cited by 157
Hu, X., Weng, Z., Chu, C. T., Zhang, L., Cao, G., Gao, Y., Signore, A. P., Zhu, J., Hastings, T. G., Greenamyre, J. T., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4589-10.2011 · Cited by 156
Spieles-Engemann, A. L., Behbehani, M. M., Collier, T. J., Wohlgenant, S. L., Steece‐Collier, K., Paumier, K. L., Daley, B. F., Gombash, S. E., Madhavan, L., Mandybur, G. T., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.009 · Cited by 155
Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP
Seniuk, N. A., Tatton, W. G., & Greenwood, C. E. (1990) · Brain Research · doi:10.1016/0006-8993(90)91055-l · Cited by 153
Schuler, F., & Casida, J. E. (2001) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(01)00183-9 · Cited by 152
Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates
Quik, M., Parameswaran, N., McCallum, S. E., Bordia, T., Bao, S., McCormack, A. L., Kim, A., Tyndale, R. F., Langston, J. W., & Monte, D. A. D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04078.x · Cited by 151
Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.
Liu, Y., Roghani, A., & Edwards, R. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9074 · Cited by 151
Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions
Vingerhoets, F. J. G., Snow, B. J., Tetrud, J. W., Langston, J. W., Schulzer, M., & Calne, D. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360513 · Cited by 151
Mitochondrial alterations in Parkinson’s disease: new clues
Vila, M., Ramonet, D., & Perier, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05604.x · Cited by 150
Self-citationIncreased striatal dopamine turnover following acute administration of rotenone to mice
Thiffault, C., Langston, J. W., & Monte, D. A. D. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02960-7 · Cited by 149
Blandini, F., Cova, L., Armentero, M., Zennaro, E., Levandis, G., Bossolasco, P., Calzarossa, C., Mellone, M., Busca, G. A., Deliliers, G. L., et al. (2010) · Cell Transplantation · doi:10.3727/096368909x479839 · Cited by 147
Grealish, S., Mattsson, B., Draxler, P., & Björklund, A. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07265.x · Cited by 147
Limitations on the use of the C57BL/6 mouse in the tail suspension test
Mayorga, A. J., & Lucki, I. (2001) · Psychopharmacology · doi:10.1007/s002130100687 · Cited by 147
Akt Suppresses Retrograde Degeneration of Dopaminergic Axons by Inhibition of Macroautophagy
Cheng, H.-C., Kim, S. R., Oo, T. F., Kareva, T., Yarygina, O., Rzhetskaya, M., Wang, C., During, M. J., Tallóczy, Z., Tanaka, K., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5519-10.2011 · Cited by 145
Cited by
Rodent models in neuroscience research: is it a rat race?
Ellenbroek, B., & Youn, J. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.026120 · Cited by 627
Val-Laillet, D., Aarts, E., Weber, B., Ferrari, M., Quaresima, V., Stoeckel, L. E., Alonso-Alonso, M., Audette, M., Malbert, C. H., & Stice, E. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.03.016 · Cited by 442
Nava Catorce, M., & Gevorkian, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151204122017 · Cited by 356
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
“MPP+ inhibits cellular respiration by direct inhibition of the mitochondrial transport chain leading to neuronal injury and death [12].”
BackgroundAlpha-synuclein and tau: teammates in neurodegeneration?
Moussaud, S., Jones, D. R., Moussaud-Lamodière, E. L., Delenclos, M., Ross, O. A., & McLean, P. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-43 · Cited by 287
Metadata
- Authors
- Bové, J., & Perier, C.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 211
- Pages
- 51-76
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2088318694
- Cited by
- 506
- References
- 329
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.